Summary by Futu AI
Conchinobio released on April 29, 2024 its unaudited first quarter report for the three months ended March 31, 2024. The report showed that the company's operating income was RMB 1.14 billion, an increase of 13.65% year-on-year. However, the company had a net loss attributable to shareholders of listed companies of RMB 1.7 billion and basic earnings per share of negative $0.69. R&D investments totaled RMB 1.24 billion and accounted for 108.79% of operating income, down 41.25 percentage points from the same period last year. The company's total assets were RMB85.69 billion, down 8.05% year-on-year. In the quarter, the company's total assets and total liabilities decreased, resulting in an investment loss of approximately RMB 7051 million, as the drug was no longer included in the merger scope...Show More